relative to a state parks pass pilot program for recovery centers and community mental health centers.

2026 Regular Session Introduced by Kevin Avard and 6 co-sponsors

Expands California’s controlled-substances list to include a wide range of synthetic opioids and fentanyl derivatives, enabling felony charges for possession, distribution, and tra

Inexpedient to Legislate: MA VV 04/23/2026 HJ 11

Purpose

To update the state Controlled Substances Act by adding a broad set of recently encountered synthetic opioids, opioid analogues, and related novel psychoactive compounds to the statutory controlled-substance lists. The bill is intended to give law enforcement and prosecutors explicit statutory authority to regulate, investigate, and prosecute possession, manufacture, distribution, and trafficking of newly emergent synthetic opioids and certain stimulant and cannabinoid analogues.

Key provisions and changes

Expands the list of controlled “opiates / opioids” to name numerous specific compounds (and their isomers, esters, ethers and salts), including but not limited to:

Brorphine; AP-237 and related AP compounds; AP-238
Multiple U-series opioids and many substituted/difluoro/alkyl variants of U-47700, U-51754, U-47931E and related designations
Several nitazene-class substances (e.g., butonitazene, flunitazene, protonitazene and parent nitazene family members)
Additional benzimidazole (nitazene) structural derivatives (a new, generically described subclass)

Broadens "fentanyl derivatives" coverage by clarifying that any compound structurally derived from fentanyl (by substitutions on key moieties) is included unless specifically excepted or FDA‑approved. Lists specific fluoro- and other fentanyl analogs (e.g., 2‑fluorofentanyl, 3‑fluorofentanyl, tetrahydrofuran fentanyl, 4‑FIBF, 4‑FBF).

Adds/updates other controlled‑substance categories:

A new nitazene derivatives subdivision with a chemical‑class definition to capture many analogues.
Clarifies/updates listings for certain tryptamines (e.g., 5‑MeO‑MiPT), substituted cathinones, and synthetic cannabinoids (e.g., indazole carboxaldehydes), including salts, isomers, homologues and related derivatives.

Explicit exceptions: compounds contained in FDA‑approved pharmaceutical products, compounds used legitimately in manufacturing not intended for human ingestion, and authorized research at recognized institutions are not intended to be covered where specified.

Who is affected

Criminal justice actors: law enforcement, prosecutors, and courts (expanded statutory basis for charging and prosecuting possession/trafficking of newly emergent synthetics).

Public health and overdose‑response systems: may affect surveillance, toxicology, and treatment strategies.

Laboratories and forensic units: will need updated reference standards and analytical methods.

Researchers, manufacturers, and legitimate medical/pharmaceutical entities: subject to specified exceptions but may face new compliance steps.

Individuals who possess, distribute, or manufacture listed substances: exposed to criminal penalties under controlled‑substance laws.

Implementation, timeline & practical notes

Effective as statute (Chapter 757) following Governor’s approval on October 13, 2025.

Enforcement will require updated training for police and prosecutors, and updated forensic capability to identify newly scheduled compounds.

The law uses broad chemical‑class language plus enumerated examples to capture both named substances and many structural analogues. This broad scope aims to limit the ability of traffickers to evade control by minor molecular modifications but also raises implementation considerations for research and legitimate industrial uses.

Bill

relative to a state parks pass pilot program for recovery centers and community mental health centers.

SB 450 — Novel Opioid Control Act of 2025

Purpose

Key provisions and changes

Who is affected

Implementation, timeline & practical notes

Create your proposal